Related Experiment Videos
Clinical trials in head injury
1Division of Neurosurgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0631, USA.
Abstract:
Secondary brain damage, following severe head injury is considered to be a major cause for bad outcome. Impressive reductions of the extent of brain damage in experimental studies have raised high expectations for cerebral neuroprotective treatment, in the clinic. Therefore multiple compounds were and are being evaluated in trials. In this review we discuss the pathomechanisms of traumatic brain damage, based upon their clinical importance. The role of hypothermia, mannitol, barbiturates, steroids, free radical scavengers, arachidonic acid inhibitors, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, and potassium channel blockers, will be discussed. The importance of a uniform strategic approach for evaluation of potentially interesting new compounds in clinical trials, to ameliorate outcome in patients with severe head injury, is proposed. To achieve this goal, two nonprofit organizations were founded: the European Brain Injury Consortium (EBIC) and the American Brain Injury Consortium (ABIC). Their aim lies in conducting better clinical trials, which incorporate lessons learned from previous trials, such that the succession of negative, or incomplete studies, as performed in previous years, will cease.
Insights
Secondary brain damage after head injury significantly impacts patient outcomes. This review explores neuroprotective treatments and proposes a unified strategy for clinical trials to improve severe head injury recovery.
Area of Science:
- Neuroscience
- Clinical Neurology
- Pharmacology
Background:
- Secondary brain damage is a primary cause of poor outcomes following severe head injury.
- Experimental studies show promising reductions in brain damage, leading to clinical trials for neuroprotective treatments.
Purpose of the Study:
- To review the pathomechanisms of traumatic brain damage and their clinical significance.
- To discuss various neuroprotective compounds and their roles in clinical trials.
- To propose a uniform strategic approach for evaluating new compounds in severe head injury patients.
Main Methods:
- Review of existing literature on traumatic brain injury (TBI) pathomechanisms.
- Discussion of clinical trial data for various neuroprotective agents.
- Analysis of strategies for improving clinical trial design and execution.
Main Results:
- Identified key pathomechanisms of traumatic brain damage relevant to clinical outcomes.
- Evaluated the potential and limitations of hypothermia, mannitol, barbiturates, steroids, free radical scavengers, arachidonic acid inhibitors, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, and potassium channel blockers.
- Highlighted the need for standardized clinical trial methodologies.
Conclusions:
- A unified strategic approach is crucial for the successful evaluation of neuroprotective compounds in severe head injury.
- The European Brain Injury Consortium (EBIC) and American Brain Injury Consortium (ABIC) aim to improve clinical trial design and outcomes.
- Future clinical trials must incorporate lessons learned from past studies to avoid negative or incomplete results.